Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston.
Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC).
Tegavivint, the most advanced Wnt/β-catenin inhibitor in clinical development, targets TBL1, leading to degradation of nuclear β-catenin and inhibition of Wnt-driven oncogenic transcription. This novel approach has shown excellent tolerability and encouraging clinical activity in an ongoing Phase 1/2 aHCC trial.
📍 Poster Details
Title: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response
Date & Time: Friday, October 24, 2025 | 12:30 – 4:00 PM
Session: Poster Session B
Poster #: B135
